Patent ID: 8822172

Claim:
A method of measuring isolevuglandin and/or levuglandin ethanolamine phospholipid adducts associated with oxidative injury in a subject, the method comprising: obtaining a bodily sample suspected of including isolevuglandin and/or levuglandin ethanolamine phospholipid adducts from a subject, selectively hydrolyzing isolevuglandin and/or levuglandin ethanolamine phospholipid adducts from the sample with a phospholipase A2 (PLA2) enzyme that forms isolevuglandin and/or levuglandin 2-lysoethanolamine phospholipid derivatives, and determining the amount of isolevuglandin and/or levuglandin 2-lysoethanolamine phospholipid derivatives by mass spectrometry, wherein the amount of isolevuglandin and/or levuglandin 2-lysoethanolamine phospholipid derivatives is determinative of the level of isolevuglandin and/or levuglandin ethanolamine phospholipid adducts in the sample and indicative of the level of oxidative injury in the subject, and wherein an increased level of isolevuglandin and/or levuglandin ethanolamine phospholipid adducts in the subject compared to a control level is indicative of an increased level of oxidative injury in the subject.